Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

447 Press Releases
DateTitleCompany
06 Apr 17 Teva to Report First Quarter 2017 Financial Results on May 11, 2017 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
04 Apr 17 Teva Announces FDA Approval of AUSTEDO™ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
16 Mar 17 Teva Announces Launch of Authorized Generic of Minastrin® 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
13 Mar 17 Teva to Present at the Barclays Global Annual Healthcare Conference Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
06 Mar 17 Teva to Present at the Cowen & Company 37th Annual Healthcare Conference Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
01 Mar 17 Teva Announces Launch of Generic Pristiq® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
28 Feb 17 Teva Announces Priority Review Granted by FDA for SD-809 for Treatment of Tardive Dyskinesia Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
06 Feb 17 Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
02 Feb 17 Teva Confirms Generic Victoza® Patent Challenge in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
01 Feb 17 Teva to Report Fourth Quarter 2016 Financial Results on February 13, 2017 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
31 Jan 17 Teva Confirms District Court Decision in COPAXONE® 40 mg/mL Patent Trial Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
18 Jan 17 Teva Receives FDA Approval for VANTRELATM ER (Hydrocodone Bitartrate) Extended-Release Tablets [CII] Formulated with Proprietary Abuse Deterrence Technology Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
09 Jan 17 Teva Announces Completion of Sale of UK and Ireland Actavis Assets and Operations Following European Commission Approval Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
06 Jan 17 Teva to Present at the 35th Annual J.P. Morgan Healthcare Conference Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
05 Jan 17 Teva to Host 2017 Business Outlook Conference Call and Webcast on January 6, 2017 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
07 Dec 16 Teva to Present at the Citi 2016 Global Healthcare Conference Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
06 Dec 16 Teva Receives Positive Outcome for COPAXONE® Label in Europe Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
05 Dec 16 Teva Appoints Dipankar Bhattacharjee as President and Chief Executive Officer, Global Generic Medicines Group, Succeeding Siggi Olafsson Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
03 Oct 16 Teva Completes Acquisition of Anda, Inc. Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
05 Oct 16 Teva Announces Sale of UK and Ireland Actavis Assets and Operations Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
06 Oct 16 Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
12 Oct 16 Teva Announces Launch of Generic Beyaz® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
17 Oct 16 Teva Receives Positive Opinion from European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to Extend Indication of Trisenox® for First Line Treatment of Low- to Intermediate Risk Acute Promyelocytic Leukemia (APL) Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
20 Oct 16 Teva Announces FDA Acceptance of Resubmitted New Drug Application for SD-809 for Treatment of Chorea Associated with Huntington Disease Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
21 Nov 16 Teva Secures European Approval of Trisenox® for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia (APL) Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
02 Nov 16 CMS Establishes Unique J-Code for BENDEKA® (Bendamustine Hydrochloride) Injection Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
26 Oct 16 Teva Pharmaceuticals and IBM Expand Global Partnership to Enable Drug Development and Chronic Disease Management with Watson Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
31 Oct 16 Teva to Report Third Quarter 2016 Financial Results on November 15, 2016 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
07 Nov 16 Teva Announces Approval of Generic Tribenzor® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
08 Nov 16 Teva Announces Appointment of New Chief Legal Officer Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.